PEGS 2022: Isogenica showcases plans for implementing machine learning tools
Isogenica is attending PEGS Europe: Protein and Antibody Engineering Summit, 14-16th November 2022
Isogenica is delighted to announce we’re attending PEGS Europe 2022.
Isogenica’s KTP Associate, Ben Wagstaffe, will be travelling to Barcelona to showcase our plans for implementing machine learning tools to speed up and improve how we make high quality VHH antibodies for next-generation biotherapeutics. Ben will present a poster on ‘Incorporating machine learning into a VHH candidate discovery pipeline‘.
This work is a collaboration with the University of Nottingham and Aston University through a Knowledge Transfer Partnership (KTP), funded by UKRI through Innovate UK.
To learn more about how machine learning can be applied to VHH discovery and optimisation download the poster here:
Further Information
Isogenica is a biotechnology company specializing in the discovery and development of small format single chain VHH antibodies. We are leaders in our domain, having developed a fully synthetic, in vitro plug-and-play cassette-based approach to efficiently generate combinations of bi- and tri-specific biotherapeutics. Drawing on more than 20 years at the forefront of antibody discovery and engineering, we have built a unique and proven engine for biotherapeutic development and a deep pipeline including two clinical stage assets and more than ten partnered pre-clinical and discovery stage programmes.
Contact
Harriet Boyd,
Business Development & Marketing Executive
T +44 1799 533 680
